Protara Therapeutics, Inc. (TARA)
3.87
+0.02
(+0.52%)
USD |
NASDAQ |
Aug 24, 16:00
3.88
+0.01
(+0.26%)
After-Hours: 20:00
Protara Therapeutics Enterprise Value : 88.91M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 88.91M |
| August 21, 2026 | 87.73M |
| August 20, 2026 | 90.68M |
| August 19, 2026 | 94.23M |
| August 18, 2026 | 95.41M |
| August 17, 2026 | 95.41M |
| August 14, 2026 | 94.82M |
| August 13, 2026 | 93.05M |
| August 12, 2026 | 90.09M |
| August 11, 2026 | 91.27M |
| August 10, 2026 | 103.09M |
| August 07, 2026 | 103.68M |
| August 06, 2026 | 102.50M |
| August 05, 2026 | 96.59M |
| August 04, 2026 | 97.18M |
| August 03, 2026 | 94.82M |
| July 31, 2026 | 91.86M |
| July 30, 2026 | 98.36M |
| July 29, 2026 | 85.36M |
| July 28, 2026 | 93.05M |
| July 27, 2026 | 98.95M |
| July 24, 2026 | 97.77M |
| July 23, 2026 | 98.95M |
| July 22, 2026 | 101.32M |
| July 21, 2026 | 101.91M |
| Date | Value |
|---|---|
| July 20, 2026 | 100.73M |
| July 17, 2026 | 102.50M |
| July 16, 2026 | 101.32M |
| July 15, 2026 | 103.68M |
| July 14, 2026 | 101.91M |
| July 13, 2026 | 107.23M |
| July 10, 2026 | 115.50M |
| July 09, 2026 | 108.41M |
| July 08, 2026 | 103.09M |
| July 07, 2026 | 112.54M |
| July 06, 2026 | 101.32M |
| July 02, 2026 | 100.14M |
| July 01, 2026 | 98.95M |
| June 30, 2026 | 85.96M |
| June 29, 2026 | 96.30M |
| June 26, 2026 | 94.10M |
| June 25, 2026 | 87.49M |
| June 24, 2026 | 89.15M |
| June 23, 2026 | 87.49M |
| June 22, 2026 | 93.55M |
| June 18, 2026 | 86.39M |
| June 17, 2026 | 91.35M |
| June 16, 2026 | 77.03M |
| June 15, 2026 | 84.19M |
| June 12, 2026 | 81.99M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.190M |
| Brainstorm Cell Therapeutics, Inc. | 12.39M |
| Summit Therapeutics, Inc. | 9.426B |
| Kezar Life Sciences, Inc. | -11.12M |
| Clene, Inc. | 69.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.67M |
| Total Expenses (Quarterly) | 21.67M |
| EPS Diluted (Quarterly) | -0.3552 |
| Earnings Yield | -34.98% |
| Normalized Earnings Yield | -34.98 |